
Fred H. Mull
Examiner (ID: 4132, Phone: (571)272-6975 , Office: P/3648 )
| Most Active Art Unit | 3662 |
| Art Unit(s) | 3662, 3648, 3646, 3645 |
| Total Applications | 1510 |
| Issued Applications | 1110 |
| Pending Applications | 115 |
| Abandoned Applications | 303 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20328399
[patent_doc_number] => 12458656
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-04
[patent_title] => Advantageous anti-HCV combination therapy
[patent_app_type] => utility
[patent_app_number] => 19/215054
[patent_app_country] => US
[patent_app_date] => 2025-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 59
[patent_no_of_words] => 33250
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19215054
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/215054 | Advantageous anti-HCV combination therapy | May 20, 2025 | Issued |
Array
(
[id] => 20465382
[patent_doc_number] => 12521411
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-13
[patent_title] => Azithromycin premix formulation and product, methods of preparing same, and methods of using same
[patent_app_type] => utility
[patent_app_number] => 19/196922
[patent_app_country] => US
[patent_app_date] => 2025-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 5764
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19196922
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/196922 | Azithromycin premix formulation and product, methods of preparing same, and methods of using same | May 1, 2025 | Issued |
Array
(
[id] => 20163850
[patent_doc_number] => 20250255896
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-14
[patent_title] => NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF IN INTRAVENOUS FORMULATIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 19/193361
[patent_app_country] => US
[patent_app_date] => 2025-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15011
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19193361
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/193361 | Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof | Apr 28, 2025 | Issued |
Array
(
[id] => 20033263
[patent_doc_number] => 20250171485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-29
[patent_title] => CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE
[patent_app_type] => utility
[patent_app_number] => 19/025101
[patent_app_country] => US
[patent_app_date] => 2025-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14791
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19025101
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/025101 | Crystal forms of beta-nicotinamide mononucleotide | Jan 15, 2025 | Issued |
Array
(
[id] => 19846724
[patent_doc_number] => 20250092075
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-20
[patent_title] => GLYCOSYLATION METHOD INVOLVING TRIVALENT IODINE REAGENT
[patent_app_type] => utility
[patent_app_number] => 18/964637
[patent_app_country] => US
[patent_app_date] => 2024-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16830
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 244
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18964637
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/964637 | Glycosylation method involving trivalent iodine reagent | Nov 30, 2024 | Issued |
Array
(
[id] => 19855792
[patent_doc_number] => 12258616
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-25
[patent_title] => Methods and kits useful for diagnosis of human papillomavirus (HPV)
[patent_app_type] => utility
[patent_app_number] => 18/889398
[patent_app_country] => US
[patent_app_date] => 2024-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 28
[patent_no_of_words] => 45000
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 296
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18889398
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/889398 | Methods and kits useful for diagnosis of human papillomavirus (HPV) | Sep 18, 2024 | Issued |
Array
(
[id] => 19418441
[patent_doc_number] => 20240294564
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => CD206 TARGETED DRUG DELIVERY VEHICLES CARRYING NOVEL BISPHOSPHONATE DRUG PAYLOADS VIA A DEGRADABLE LINKER
[patent_app_type] => utility
[patent_app_number] => 18/664971
[patent_app_country] => US
[patent_app_date] => 2024-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19118
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18664971
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/664971 | CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker | May 14, 2024 | Issued |
Array
(
[id] => 19402154
[patent_doc_number] => 20240285665
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE
[patent_app_type] => utility
[patent_app_number] => 18/629820
[patent_app_country] => US
[patent_app_date] => 2024-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34979
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18629820
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/629820 | Inhibitors of adenosine 5'-nucleotidase | Apr 7, 2024 | Issued |
Array
(
[id] => 19279942
[patent_doc_number] => 20240216415
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES
[patent_app_type] => utility
[patent_app_number] => 18/602969
[patent_app_country] => US
[patent_app_date] => 2024-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25390
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18602969
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/602969 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Mar 11, 2024 | Pending |
Array
(
[id] => 19279941
[patent_doc_number] => 20240216414
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus
[patent_app_type] => utility
[patent_app_number] => 18/603143
[patent_app_country] => US
[patent_app_date] => 2024-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22782
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 538
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18603143
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/603143 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | Mar 11, 2024 | Pending |
Array
(
[id] => 19318289
[patent_doc_number] => 20240239831
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => METHODS OF PREPARING REDUCED NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/598617
[patent_app_country] => US
[patent_app_date] => 2024-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8016
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18598617
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/598617 | METHODS OF PREPARING REDUCED NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF | Mar 6, 2024 | Pending |
Array
(
[id] => 20432528
[patent_doc_number] => 12502400
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-23
[patent_title] => Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
[patent_app_type] => utility
[patent_app_number] => 18/583315
[patent_app_country] => US
[patent_app_date] => 2024-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 4650
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18583315
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/583315 | Method of preventing of systemic-to-pulmonary-artery shunt thrombosis | Feb 20, 2024 | Issued |
Array
(
[id] => 19331285
[patent_doc_number] => 20240245715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => SYNERGISTIC FORMULATIONS OF ADENOSINE RECEPTOR MODULATING AGENTS AND ANTICHOLINERGICS
[patent_app_type] => utility
[patent_app_number] => 18/442232
[patent_app_country] => US
[patent_app_date] => 2024-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13247
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18442232
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/442232 | SYNERGISTIC FORMULATIONS OF ADENOSINE RECEPTOR MODULATING AGENTS AND ANTICHOLINERGICS | Feb 14, 2024 | Pending |
Array
(
[id] => 19578739
[patent_doc_number] => 12144821
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-11-19
[patent_title] => Selective 3-prenyl 5-methyl ether, 7-o-rhamnoside flavone for the treatment of hepatic cancer
[patent_app_type] => utility
[patent_app_number] => 18/431303
[patent_app_country] => US
[patent_app_date] => 2024-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 6079
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18431303
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/431303 | Selective 3-prenyl 5-methyl ether, 7-o-rhamnoside flavone for the treatment of hepatic cancer | Feb 1, 2024 | Issued |
Array
(
[id] => 19641351
[patent_doc_number] => 20240415871
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => METHODS FOR TREATING ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/425707
[patent_app_country] => US
[patent_app_date] => 2024-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22294
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18425707
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/425707 | METHODS FOR TREATING ALZHEIMER'S DISEASE | Jan 28, 2024 | Abandoned |
Array
(
[id] => 19707809
[patent_doc_number] => 20250017951
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => ALTERING CANCER CELLULAR FUNCTIONS THROUGH PROTON MOPPING
[patent_app_type] => utility
[patent_app_number] => 18/425648
[patent_app_country] => US
[patent_app_date] => 2024-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2000
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18425648
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/425648 | ALTERING CANCER CELLULAR FUNCTIONS THROUGH PROTON MOPPING | Jan 28, 2024 | Abandoned |
Array
(
[id] => 19232143
[patent_doc_number] => 20240189334
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => METHODS FOR TREATMENT OF VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 18/394488
[patent_app_country] => US
[patent_app_date] => 2023-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39911
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18394488
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/394488 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | Dec 21, 2023 | Abandoned |
Array
(
[id] => 19854454
[patent_doc_number] => 12257264
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-25
[patent_title] => Combination therapy for HIV with adenosine derivative and capsid inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/391316
[patent_app_country] => US
[patent_app_date] => 2023-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 27011
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18391316
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/391316 | Combination therapy for HIV with adenosine derivative and capsid inhibitors | Dec 19, 2023 | Issued |
Array
(
[id] => 19439911
[patent_doc_number] => 12090136
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Apparatus for treating Benign Prostatic Hyperplasia
[patent_app_type] => utility
[patent_app_number] => 18/528691
[patent_app_country] => US
[patent_app_date] => 2023-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 12
[patent_no_of_words] => 21868
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 129
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18528691
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/528691 | Apparatus for treating Benign Prostatic Hyperplasia | Dec 3, 2023 | Issued |
Array
(
[id] => 19049277
[patent_doc_number] => 20240091246
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF COVID-19
[patent_app_type] => utility
[patent_app_number] => 18/522134
[patent_app_country] => US
[patent_app_date] => 2023-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3239
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18522134
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/522134 | METHODS AND COMPOSITIONS FOR TREATMENT OF COVID-19 | Nov 27, 2023 | Abandoned |